Triple therapy aims to halt advanced melanoma in its tracks
NCT ID NCT04091750
First seen Mar 09, 2026 · Last updated Jun 16, 2026 · Updated 14 times
Summary
This study tests a combination of three drugs (nivolumab, ipilimumab, and cabozantinib) in 14 adults with advanced melanoma that cannot be surgically removed. Participants receive the triple therapy for 12 weeks, then switch to two drugs for up to 2 years. The goal is to see how long the cancer stays under control and to monitor side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia, 20007, United States
-
Medstar Franklin Square Medical Center, Harry and Jeanette Weinberg Cancer Institute
Baltimore, Maryland, 21237, United States
Conditions
Explore the condition pages connected to this study.